Video - Results from #10

ASCO GU 2021 Bladder and Kidney Cancer VL

Search

A Preplanned Exploratory Biomarker Analysis in the ctDNA-Positive Patient Population of IMvigor010 - Tom Powles Details IMvigor010 is a prospective, randomized, adjuvant trial, testing atezolizumab versus best supportive care in a high-risk bladder cancer population. Overall, the trial did not meet its progression-free survival or overall survival endpoints. Thomas Powles, MD joins Alicia Morgans, MD, MPH, highlighting the preplanned, exploratory biomarker analysis that measured ctDNA at baseline after cystectomy,...
High-Risk Non-Muscle-Invasive Bladder Cancer - Which Patients Benefit from a Radical Cystectomy - Anne Schuckman Details Anne Schuckman, MD, MBBS, discusses which patients with high-risk non-muscle-invasive bladder cancer may benefit from radical cystectomy with Ashish Kamat, MD. What’s clinically difficult in high-risk non-muscle-invasive bladder cancer is that 50% of patients undergoing TURBT plus intravesical therapy have long-term recurrence-free survival, however, 20% will progress to muscle-invasive bladder ca...
Efficacy by Duration or Number of Cycles of First-line Chemotherapy in the JAVELIN Bladder 100 Study - Petros Grivas Details Avelumab first-line maintenance therapy is approved in the United States for patients with advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy based on significantly prolonged overall survival versus best supportive care alone. (median 21.4 months versus 14.3 months; HR 0.69, 95% CI 0.56-0.86) as reported in the phase III JAVELIN Bladder 100 trial...
SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) - A Clinical Trial for the Novel Administration of Immunotherapy for Bladder Cancer- Dickon Hayne Details Several solid tumors, including bladder cancer, can demonstrate good responses to systemic immuno-oncology agents, however, the efficacy of IO agents in localized bladder carcinoma remains less clear, although numerous trials are underway. In this conversation, Ashish Kamat, MD, MBBS, and Dickon Hayne, MD, MBBS, highlight one such immuno-oncology agent, durvalumab, an antibody against the immune c...
Immunotherapy in Advanced Urothelial Carcinoma - Ali Khaki Details Ali Khaki and Petros Grivas come together to discuss three studies presented at the 2021 ASCO GU meeting, on immunotherapy in advanced urothelial carcinoma (aUC) as well as a recently published paper in this disease advanced bladder cancer which aimed to develop a prognostic model for overall survival (OS) in patients receiving first-line immune checkpoint inhibitors for advanced urothelial cancer...
A New Standard of Care in Treatment of Advanced Urothelial Carcinoma from JAVELIN Bladder 100 - Cora Sternberg Details The analysis of the JAVELIN Bladder 100 trial, efficacy by duration or number of cycles of first-line chemotherapy presented at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) helped clinicians understand, the outcomes of avelumab from the JAVELIN 100 trial. The number of cycles (cycle every 3 weeks), of first-line chemotherapy. The optimal duration of firs...
Adjuvant Study of Immune Checkpoint Blockade in Patients with Urothelial Carcinoma - Matthew Galsky Details First Results from the Phase 3 CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma were presented at ASCO GU 2021 and are the topic of discussion between Matthew Galsky, MD and Alicia Morgans, MD, MPH. CheckMate274 is a phase 3, randomized, double-blind, multicenter trial comparing nivolumab and placebo i...